Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
暂无分享,去创建一个
L. Schwartz | R. Herbst | F. Hirsch | J. Bradley | K. Kelly | D. Gandara | S. Ramalingam | N. Rizvi | T. Stinchcombe | V. Papadimitrakopoulou | P. Mack | N. Leighl | J. Crawford | J. Wade | M. Redman | W. Irvin | Katherine Minichiello | Jieling Miao | S. Reddy | K. Minichiello | F. Hirsch
[1] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[2] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[3] J. Allison,et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.
[4] R. Herbst,et al. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) , 2019, Journal of Thoracic Oncology.
[5] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[6] A. Mansfield,et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.
[7] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[8] R. Herbst,et al. Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[10] Jeffrey,et al. Treated PI 3 K-Positive Patients with Stage IV Squamous Cell Lung Cancer ( Lung-MAP Sub-Study ) , 2019 .
[11] David Wholley,et al. Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 , 2015, Clinical Cancer Research.
[12] A. Wozniak,et al. Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients. , 2018 .
[13] M. Filetti,et al. Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes , 2020, Journal for ImmunoTherapy of Cancer.
[14] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[15] K. Steele,et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.
[16] K. Syrigos,et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.
[17] A. Cherniack,et al. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.
[18] Keunchil Park,et al. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Herbst,et al. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway – Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) , 2019 .
[20] C. Drake. Combination immunotherapy approaches. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[22] L. Schwartz,et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. , 2020, The Lancet. Oncology.